

Custom Antibody Market by Service (Development, Purification, Labelling), Type (Monoclonal, Recombinant), Source (Rabbit, Mice), Application (Research, Therapeutics), Indication (Oncology, Immunology), End User (Biopharma, CROs) - Global Forecast to 2028

Market Report | 2023-02-28 | 278 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global custom antibody market size is projected to reach USD 860 million by 2028 from USD 548 million in 2023, at a CAGR of 9.4% during the forecast period. Factors such as increasing investment for the development of ADCs and rising research in structure-based drug design and therapeutics mAbs of custom antibody, are driving the market growth at a faster pace.

"The recombinant antibodies segment is likely to grow at highest CAGR during the forecast period of 2023-2028."

On the basis of type, the custom antibody market is segmented into monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and others. The recombinant antibodies segment is projected to grow at the highest CAGR during the forecast period. The growth is attributed to low immunogenicity and increased research reproducibility offered by recombinant antibodies. This is likely to have a positive impact on segmental growth.

"The mice source is expected to hold a dominant share in 2023."

Based on the source, the market is segmented into mice, rabbits, and others. The mice segment is expected to grow at a faster pace during the forecast period due to factors that mice are conventionally preferred hosts for mAbs production for research purposes.

"In 2022, the research applications segment held a dominant share."

Based on application, the custom antibody market is segmented into research and therapeutic applications. The research

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

applications segment held a dominant share of the custom antibody market. Adoption of custom antibody in research and drug discovery & development is one of the major factors anticipated to project the market growth

"The oncology segment is likely to grow at highest CAGR during the forecast period of 2023-2028."

Based on indication, the custom antibody market is segmented into oncology, infectious diseases, immunology, neurobiology, cardiovascular diseases, and others. The oncology indication segment held a dominant share of the custom antibody market, in 2022. The growing use of mAbs and custom antibody in cancer treatment is one of the major factor anticipated to project market growth.

"Asia Pacific region is likely to grow at faster pace."

The custom antibody market is divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America accounted for the dominant share of custom antibody market. The dominance of the region is attributable to various factors such as the presence of dominant and key market players in the region coupled with the ongoing research activities of custom antibody. Asia Pacific region is likely to grow at a faster pace owing to various factors such as the growing awareness of personalized therapeutics, rising research initiatives undertaken by the government for antibody development in the region, and the emergence of new market players in the custom antibody market.

The primary interviews conducted for this report can be categorized as follows:

-□By Respondent: Supply Side- 60%, and Demand Side - 40%

-□By Designation (Supply Side): Managers - 45%, CXOs & Directors - 25%, Executives- 15%, Other -15.0%

-□By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%

Lists of Companies Profiled in the Report:

-□Thermo Fisher Scientific (US)

-□GenScript (China)

-□Abcam plc. (UK)

-□Cell Signaling Technology, Inc (US)

-□Bio-Rad Laboratories, Inc (US)

-□Merck KGaA (Germany)

-□Agilent Technologies, Inc (Germany)

-□PerkinElmer, Inc (US)

-□Rockland Immunochemicals, Inc (US)

-□ProMab Biotechnologies, Inc (US)

-□Innovagen AB (Sweden)

-□OriGene Technologies (US)

-□Bio-Techne (US)

-□Creative Diagnostics (US)

-□Sino Biological, Inc (China)

-□RayBiotech Life, Inc (US)

-□Abbotec, Inc (US)

-□ProSci (US)

-□Boster Biological Technology (US)

-□CUSABIO Technology LLC (US)

-□Biointron (China)

-□Kaneka Eurogentech S.A. (Belgium)

-□Creative Biolabs (US)

-□Envigo (US)

-□Imgenex India Pvt. Ltd (India).

Research Coverage:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

This report provides a detailed picture of the custom antibody market. It aims at estimating the size and future growth potential of the market across different segments, such as service, type, source, application, indication, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall custom antibody market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

Table of Contents:

1	INTRODUCTION	26
1.1	STUDY OBJECTIVES	26
1.2	MARKET DEFINITION	26
1.2.1	INCLUSIONS AND EXCLUSIONS	27
1.3	MARKET SCOPE	28
1.3.1	MARKETS COVERED	28
1.3.2	YEARS CONSIDERED	29
1.4	CURRENCY CONSIDERED	29
1.5	LIMITATIONS	29
1.6	STAKEHOLDERS	30
1.7	SUMMARY OF CHANGES	30
1.7.1	RECESSION IMPACT	30
2	RESEARCH METHODOLOGY	32
2.1	RESEARCH APPROACH	32
FIGURE 1	RESEARCH DESIGN	32
2.1.1	SECONDARY DATA	33
2.1.2	PRIMARY DATA	33
FIGURE 2	CUSTOM ANTIBODY MARKET: PRIMARY RESPONDENTS	34
2.2	MARKET ESTIMATION METHODOLOGY	34
2.2.1	AVERAGE MARKET SIZE ESTIMATION (2022)	35
FIGURE 3	AVERAGE MARKET SIZE ESTIMATION (2022): CUSTOM ANTIBODY MARKET	35
FIGURE 4	MARKET SIZE ESTIMATION: REVENUE-BASED ESTIMATION METHODOLOGY	36
2.3	DATA TRIANGULATION APPROACH	37
FIGURE 5	DATA TRIANGULATION METHODOLOGY	37
2.4	GROWTH RATE ASSUMPTIONS	38
2.5	GROWTH FORECAST	38
FIGURE 6	GROWTH RATE ANALYSIS	38
2.6	RISK ASSESSMENT	39
2.7	INSIGHTS FROM PRIMARY EXPERTS	39
2.8	CUSTOM ANTIBODY MARKET: RECESSION IMPACT	40
TABLE 1	GLOBAL INFLATION RATE PROJECTION, 2021-2027 (% GROWTH)	40
TABLE 2	US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)	41
TABLE 3	US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)	41
3	EXECUTIVE SUMMARY	42

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 7 □ CUSTOM ANTIBODY MARKET, BY SERVICE, 2023 VS. 2028 □42

FIGURE 8 □ CUSTOM ANTIBODY MARKET SHARE, BY TYPE, 2023 VS. 2028 □43

FIGURE 9 □ CUSTOM ANTIBODY MARKET SHARE, BY SOURCE, 2023 VS. 2028 □44

FIGURE 10 □ CUSTOM ANTIBODY MARKET SHARE, BY APPLICATION, 2023 VS. 2028 □44

FIGURE 11 □ CUSTOM ANTIBODY MARKET SHARE, BY INDICATION, 2023 VS. 2028 □45

FIGURE 12 □ CUSTOM ANTIBODY MARKET SHARE, BY END USER, 2023 VS. 2028 □46

FIGURE 13 □ CUSTOM ANTIBODY MARKET: GEOGRAPHICAL SNAPSHOT □47

4 □ PREMIUM INSIGHTS □48

4.1 □ CUSTOM ANTIBODY MARKET OVERVIEW □48

FIGURE 14 □ RISING DEMAND FOR MONOCLONAL ANTIBODIES IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET □48

4.2 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET SHARE, BY TYPE & COUNTRY (2022) □49

FIGURE 15 □ MONOCLONAL ANTIBODIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 □49

4.3 □ CUSTOM ANTIBODY MARKET SHARE, BY SOURCE (2022) □49

FIGURE 16 □ MICE SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 □49

4.4 □ CUSTOM ANTIBODY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES □50

FIGURE 17 □ ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD □50

5 □ MARKET OVERVIEW □51

5.1 □ INTRODUCTION □51

5.2 □ MARKET DYNAMICS □51

FIGURE 18 □ CUSTOM ANTIBODY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES □51

TABLE 4 □ CUSTOM ANTIBODY MARKET: IMPACT ANALYSIS □52

5.2.1 □ DRIVERS □52

5.2.1.1 □ Rising research activities and funding investments for antibody development □52

5.2.1.2 □ Growing use of custom antibodies in precision medicine □53

5.2.1.3 □ Use of antibodies in biomarker identification and validation □53

5.2.1.4 □ Quality concerns over catalog antibodies □54

5.2.2 □ RESTRAINTS □54

5.2.2.1 □ High costs and complexities associated with antibody development □54

5.2.3 □ OPPORTUNITIES □55

5.2.3.1 □ Emerging markets □55

5.2.3.2 □ Rising therapeutic applications for mAbs □55

FIGURE 19 □ NUMBER OF APPROVED ANTIBODY THERAPEUTICS (2016?2022) □56

5.2.4 □ CHALLENGES □56

5.2.4.1 □ Challenges associated with immunization of host animals □56

5.2.4.2 □ Presence of alternative antibodies □57

5.3 □ VALUE CHAIN ANALYSIS □57

FIGURE 20 □ CUSTOM ANTIBODY MARKET: VALUE-CHAIN ANALYSIS □57

5.4 □ ECOSYSTEM ANALYSIS □59

FIGURE 21 □ CUSTOM ANTIBODY MARKET: ECOSYSTEM ANALYSIS □59

5.4.1 □ ROLE IN ECOSYSTEM □59

5.5 □ PORTER'S FIVE FORCES ANALYSIS □60

TABLE 5 □ CUSTOM ANTIBODY MARKET: PORTER'S FIVE FORCES ANALYSIS □60

5.5.1 □ THREAT OF NEW ENTRANTS □60

5.5.2 □ THREAT OF SUBSTITUTES □60

5.5.3 □ BARGAINING POWER OF SUPPLIERS □61

5.5.4 □ BARGAINING POWER OF BUYERS □61

5.5.5 □ DEGREE OF COMPETITION □61

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.6	PATENT ANALYSIS	62
	FIGURE 22	CUSTOM ANTIBODY MARKET: PATENT ANALYSIS
5.7	PRICING ANALYSIS	62
5.7.1	AVERAGE SELLING PRICE TREND	62
5.7.2	INDICATIVE PRICING ANALYSIS	63
	TABLE 6	SELLING PRICE OF SERVICES PROVIDED BY GENSCRIPT
	TABLE 7	SELLING PRICE OF SERVICES PROVIDED BY ABBIOTEC, INC.
5.7.3	INDICATIVE PRICING ANALYSIS, BY REGION	63
	TABLE 8	SELLING PRICE OF CUSTOM ANTIBODY SERVICES FOR INDIA
	TABLE 9	SELLING PRICE OF CUSTOM ANTIBODY SERVICES FOR US
5.8	TECHNOLOGICAL ANALYSIS	64
5.8.1	CUSTOM ANTIBODY SERVICES	64
5.9	REGULATORY LANDSCAPE	65
5.9.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	66
	TABLE 10	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10	KEY CONFERENCES & EVENTS IN 2023	66
	TABLE 11	CUSTOM ANTIBODY MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.11	KEY STAKEHOLDERS AND BUYING CRITERIA	67
	FIGURE 23	KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES AND THEIR INFLUENCE ON BUYING PROCESS
	FIGURE 24	CUSTOM ANTIBODY MARKET: KEY BUYING CRITERIA FOR END USERS
5.12	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	68
	FIGURE 25	REVENUE SHIFT AND NEW REVENUE
6	CUSTOM ANTIBODY MARKET, BY SERVICE	69
6.1	INTRODUCTION	70
	TABLE 12	CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION)
6.2	ANTIBODY DEVELOPMENT	70
	TABLE 13	CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION)
	TABLE 14	CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY REGION, 2021-2028 (USD MILLION)
	TABLE 15	NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
	TABLE 16	EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
	TABLE 17	ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
	TABLE 18	LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
6.2.1	ANTIBODY CHARACTERIZATION	73
6.2.1.1	Crucial step in research & biopharmaceutical development for elimination of antibodies to drive market	73
	TABLE 19	CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY REGION, 2021-2028 (USD MILLION)
	TABLE 20	NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
	TABLE 21	EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
	TABLE 22	ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
	TABLE 23	LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY CHARACTERIZATION, BY COUNTRY, 2021-2028 (USD MILLION)
6.2.2	ANTIGEN PREPARATION	76
6.2.2.1	Development of research antibodies using bioinformatics tools to support market growth	76
	TABLE 24	CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY REGION, 2021-2028 (USD MILLION)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 25 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION) □78

TABLE 26 □ EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION) □78

TABLE 27 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION) □79

TABLE 28 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIGEN PREPARATION, BY COUNTRY, 2021-2028 (USD MILLION) □79

6.2.3 □ IMMUNIZATION & HYBRIDOMA PRODUCTION □79

6.2.3.1 □ Rising demand for therapeutic antibodies to drive market □79

TABLE 29 □ CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY REGION, 2021-2028 (USD MILLION) □80

TABLE 30 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION) □80

TABLE 31 □ EUROPE: CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION) □81

TABLE 32 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION) □81

TABLE 33 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNIZATION & HYBRIDOMA PRODUCTION, BY COUNTRY, 2021-2028 (USD MILLION) □82

6.3 □ ANTIBODY PRODUCTION & PURIFICATION □82

6.3.1 □ RISING NEED FOR HIGH-QUALITY THERAPEUTICS TO DRIVE MARKET □82

TABLE 34 □ CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY REGION, 2021-2028 (USD MILLION) □83

TABLE 35 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021-2028 (USD MILLION) □83

TABLE 36 □ EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021-2028 (USD MILLION) □84

TABLE 37 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021-2028 (USD MILLION) □84

TABLE 38 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY PRODUCTION & PURIFICATION, BY COUNTRY, 2021-2028 (USD MILLION) □85

6.4 □ ANTIBODY FRAGMENTATION & LABELING □85

6.4.1 □ RISING NEED FOR SPECIFIC ANTIBODIES IN DETECTION OF NEW BIOMOLECULES TO SUPPORT MARKET GROWTH □85

TABLE 39 □ CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING. BY REGION, 2021-2028 (USD MILLION) □86

TABLE 40 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021-2028 (USD MILLION) □86

TABLE 41 □ EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021-2028 (USD MILLION) □87

TABLE 42 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021-2028 (USD MILLION) □87

TABLE 43 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY FRAGMENTATION & LABELING, BY COUNTRY, 2021-2028 (USD MILLION) □88

7 □ CUSTOM ANTIBODY MARKET, BY TYPE □89

7.1 □ INTRODUCTION □90

TABLE 44 □ CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION) □90

7.2 □ MONOCLONAL ANTIBODIES □90

7.2.1 □ HIGH DEGREE OF SENSITIVITY AND PRECISION TO DRIVE MARKET □90

TABLE 45 □ CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021-2028 (USD MILLION) □91

TABLE 46 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION) □91

TABLE 47 □ EUROPE: CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION) □92

TABLE 48 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION) □92

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 49 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION) □93

7.3 □ POLYCLONAL ANTIBODIES □93

7.3.1 □ ABILITY TO BE STABLE AND WITHSTAND VARIATIONS IN TEMPERATURE TO FUEL UPTAKE □93

TABLE 50 □ CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY TYPE, BY REGION, 2021-2028 (USD MILLION) □94

TABLE 51 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION) □94

TABLE 52 □ EUROPE: CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION) □95

TABLE 53 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION) □95

TABLE 54 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION) □96

7.4 □ RECOMBINANT ANTIBODIES □96

7.4.1 □ LOW IMMUNOGENICITY AND RISING RESEARCH REPRODUCIBILITY TO DRIVE MARKET □96

TABLE 55 □ CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, BY REGION, 2021-2028 (USD MILLION) □97

TABLE 56 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION) □97

TABLE 57 □ EUROPE: CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, 2021-2028 (USD MILLION) □98

TABLE 58 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION) □98

TABLE 59 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RECOMBINANT ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION) □99

7.5 □ OTHER CUSTOM ANTIBODIES □99

TABLE 60 □ OTHER CUSTOM ANTIBODIES MARKET, BY REGION, 2021-2028 (USD MILLION) □99

TABLE 61 □ NORTH AMERICA: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □100

TABLE 62 □ EUROPE: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □100

TABLE 63 □ ASIA PACIFIC: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □101

TABLE 64 □ LATIN AMERICA: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □101

8 □ CUSTOM ANTIBODY MARKET, BY SOURCE □102

8.1 □ INTRODUCTION □103

TABLE 65 □ CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION) □103

8.2 □ MICE □103

8.2.1 □ CONVENTIONALLY PREFERRED HOSTS FOR MAB PRODUCTION TO INCREASE UPTAKE □103

TABLE 66 □ CUSTOM ANTIBODY MARKET FOR MICE, BY REGION, 2021-2028 (USD MILLION) □104

TABLE 67 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2021-2028 (USD MILLION) □104

TABLE 68 □ EUROPE: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2021-2028 (USD MILLION) □104

TABLE 69 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2021-2028 (USD MILLION) □105

TABLE 70 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR MICE, BY COUNTRY, 2021-2028 (USD MILLION) □105

8.3 □ RABBITS □105

8.3.1 □ ABILITY TO GENERATE HIGH ANTIBODY DIVERSITY WITH OPTIMAL AFFINITY TO DRIVE MARKET □105

TABLE 71 □ CUSTOM ANTIBODY MARKET FOR RABBITS, BY REGION, 2021-2028 (USD MILLION) □106

TABLE 72 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2021-2028 (USD MILLION) □106

TABLE 73 □ EUROPE: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2021-2028 (USD MILLION) □107

TABLE 74 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2021-2028 (USD MILLION) □107

TABLE 75 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RABBITS, BY COUNTRY, 2021-2028 (USD MILLION) □108

8.4 □ OTHER SOURCES □108

TABLE 76 □ CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY REGION, 2021-2028 (USD MILLION) □109

TABLE 77 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2021-2028 (USD MILLION) □109

TABLE 78 □ EUROPE: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2021-2028 (USD MILLION) □109

TABLE 79 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2021-2028 (USD MILLION) □110

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 80 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY COUNTRY, 2021-2028 (USD MILLION) □110

9 □ CUSTOM ANTIBODY MARKET, BY APPLICATION □111

9.1 □ INTRODUCTION □112

TABLE 81 □ CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION) □112

9.2 □ RESEARCH □112

9.2.1 □ RISING R&D ACTIVITIES FOR MAB-BASED THERAPEUTICS TO DRIVE MARKET □112

TABLE 82 □ CUSTOM ANTIBODY MARKET FOR RESEARCH, BY REGION, 2021-2028 (USD MILLION) □113

TABLE 83 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) □113

TABLE 84 □ EUROPE: CUSTOM ANTIBODY MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) □114

TABLE 85 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) □114

TABLE 86 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION) □115

9.3 □ THERAPEUTICS □115

9.3.1 □ GROWING USE OF MABS IN TARGETED THERAPY FOR AUTOIMMUNE DISEASES TO DRIVE MARKET □115

TABLE 87 □ CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY REGION, 2021-2028 (USD MILLION) □116

TABLE 88 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION) □116

TABLE 89 □ EUROPE: CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION) □117

TABLE 90 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION) □117

TABLE 91 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION) □118

10 □ CUSTOM ANTIBODY MARKET, BY INDICATION □119

10.1 □ INTRODUCTION □120

TABLE 92 □ CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION) □120

10.2 □ ONCOLOGY □120

10.2.1 □ GROWING USE OF MABS IN CANCER TREATMENT TO DRIVE MARKET □120

TABLE 93 □ CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY REGION, 2021-2028 (USD MILLION) □121

TABLE 94 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □121

TABLE 95 □ EUROPE: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □122

TABLE 96 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □122

TABLE 97 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □123

10.3 □ INFECTIOUS DISEASES □123

10.3.1 □ WIDE USAGE OF ANTIBODIES IN VACCINE & THERAPEUTIC DEVELOPMENT TO DRIVE MARKET □123

TABLE 98 □ CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION) □124

TABLE 99 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) □124

TABLE 100 □ EUROPE: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) □125

TABLE 101 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) □125

TABLE 102 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) □125

10.4 □ IMMUNOLOGY □126

10.4.1 □ RISING DEMAND FOR THERAPEUTIC ANTIBODIES IN IMMUNOLOGY TO DRIVE MARKET □126

TABLE 103 □ CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY REGION, 2021-2028 (USD MILLION) □126

TABLE 104 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □127

TABLE 105 □ EUROPE: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □127

TABLE 106 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □127

TABLE 107 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □128

10.5 □ NEUROBIOLOGY □128

10.5.1 □ RISING DEMAND FOR ANTIBODIES IN NEURODEGENERATIVE DISEASE TREATMENT TO DRIVE MARKET □128

TABLE 108 □ CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY REGION, 2021-2028 (USD MILLION) □129

TABLE 109 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □129

TABLE 110 □ EUROPE: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □129

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 111 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 130

TABLE 112 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021-2028 (USD MILLION) □ 130

10.6 □ CARDIOVASCULAR DISEASES □ 130

10.6.1 □ GROWING DEMAND FOR CVD BIOMARKERS TO DRIVE MARKET □ 130

TABLE 113 □ CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021-2028 (USD MILLION) □ 131

TABLE 114 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) □ 131

TABLE 115 □ EUROPE: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) □ 132

TABLE 116 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION) □ 132

TABLE 117 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021-2028 (USD MILLION) □ 133

10.7 □ OTHER INDICATIONS □ 133

TABLE 118 □ CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY REGION, 2021-2028 (USD MILLION) □ 134

TABLE 119 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) □ 134

TABLE 120 □ EUROPE: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) □ 135

TABLE 121 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) □ 135

TABLE 122 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) □ 135

11 □ CUSTOM ANTIBODY MARKET, BY END USER □ 136

11.1 □ INTRODUCTION □ 137

TABLE 123 □ CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION) □ 137

TABLE 124 □ CUSTOM ANTIBODY MARKET, BY REGION, 2021-2028 (USD MILLION) □ 137

TABLE 125 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 138

TABLE 126 □ EUROPE: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 138

TABLE 127 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 138

TABLE 128 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 139

11.2 □ PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES □ 139

11.2.1 □ RISING NEED FOR ANTIBODIES IN BIOMARKER QUANTIFICATION TO DRIVE MARKET □ 139

TABLE 129 □ CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION) □ 140

TABLE 130 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) □ 140

TABLE 131 □ EUROPE: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) □ 141

TABLE 132 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) □ 141

TABLE 133 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) □ 142

11.3 □ ACADEMIC & RESEARCH INSTITUTES □ 142

11.3.1 □ GROWING INDUSTRY-ACADEMIA COLLABORATIONS AND RISING GOVERNMENT-FUNDED INITIATIVES TO DRIVE MARKET □ 142

TABLE 134 □ CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION) □ 143

TABLE 135 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) □ 143

TABLE 136 □ EUROPE: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) □ 144

TABLE 137 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) □ 144

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 138 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) □145

11.4 □ CONTRACT RESEARCH ORGANIZATIONS □145

11.4.1 □ ABILITY TO PROVIDE SPECIALIZED SERVICES FOR PRODUCTION OF MABS & ADCS TO SUPPORT MARKET GROWTH □145

TABLE 139 □ CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021-2028 (USD MILLION) □146

TABLE 140 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION) □146

TABLE 141 □ EUROPE: CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION) □147

TABLE 142 □ ASIA PACIFIC: CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION) □147

TABLE 143 □ LATIN AMERICA: CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION) □148

12 □ CUSTOM ANTIBODY MARKET, BY REGION □149

12.1 □ INTRODUCTION □150

TABLE 144 □ CUSTOM ANTIBODY MARKET, BY REGION, 2021-2028 (USD MILLION) □150

12.2 □ NORTH AMERICA □151

FIGURE 26 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET SNAPSHOT □152

TABLE 145 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □152

TABLE 146 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION) □153

TABLE 147 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION) □153

TABLE 148 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION) □153

TABLE 149 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION) □154

TABLE 150 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION) □154

TABLE 151 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION) □154

TABLE 152 □ NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION) □155

12.2.1 □ US □155

12.2.1.1 □ Rising research in structure-based drug design and therapeutic mAbs to drive market □155

TABLE 153 □ US: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION) □156

TABLE 154 □ US: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION) □156

TABLE 155 □ US: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION) □157

TABLE 156 □ US: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION) □157

TABLE 157 □ US: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION) □157

TABLE 158 □ US: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION) □158

TABLE 159 □ US: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION) □158

12.2.2 □ CANADA □158

12.2.2.1 □ Increasing genomic research to fuel market uptake □158

TABLE 160 □ CANADA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION) □159

TABLE 161 □ CANADA: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION) □160

TABLE 162 □ CANADA: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION) □160

TABLE 163 □ CANADA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION) □160

TABLE 164 □ CANADA: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION) □161

TABLE 165 □ CANADA: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION) □161

TABLE 166 □ CANADA: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION) □161

12.2.3 □ NORTH AMERICA: RECESSION IMPACT □162

12.3 □ EUROPE □162

TABLE 167 □ EUROPE: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □163

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 168 EUROPE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION) 163

TABLE 169 EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION) 163

TABLE 170 EUROPE: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION) 164

TABLE 171 EUROPE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION) 164

TABLE 172 EUROPE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 164

TABLE 173 EUROPE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION) 165

TABLE 174 EUROPE: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION) 165

12.3.1 GERMANY 165

12.3.1.1 High investments in development of ADCs to drive market 165

TABLE 175 GERMANY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION) 166

TABLE 176 GERMANY: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION) 166

TABLE 177 GERMANY: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION) 166

TABLE 178 GERMANY: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION) 167

TABLE 179 GERMANY: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 167

TABLE 180 GERMANY: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION) 167

TABLE 181 GERMANY: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION) 168

12.3.2 UK 168

12.3.2.1 Rising pharmaceutical spending and growing life sciences industry to drive market 168

TABLE 182 UK: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION) 169

TABLE 183 UK: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION) 169

TABLE 184 UK: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION) 169

TABLE 185 UK: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION) 170

TABLE 186 UK: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 170

TABLE 187 UK: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION) 170

TABLE 188 UK: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION) 171

12.3.3 FRANCE 171

12.3.3.1 Growing pipeline of therapeutic mAbs coupled with rising research investments to support market growth 171

TABLE 189 FRANCE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION) 172

TABLE 190 FRANCE: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION) 172

TABLE 191 FRANCE: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION) 172

TABLE 192 FRANCE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION) 173

TABLE 193 FRANCE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 173

TABLE 194 FRANCE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION) 173

TABLE 195 FRANCE: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION) 174

12.3.4 ITALY 174

12.3.4.1 Increasing research activities in proteomics & genomics to drive market 174

TABLE 196 ITALY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION) 175

TABLE 197 ITALY: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION) 175

TABLE 198 ITALY: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION) 175

TABLE 199 ITALY: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION) 176

TABLE 200 ITALY: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 176

TABLE 201 ITALY: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION) 176

TABLE 202 ITALY: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION) 177

12.3.5 SPAIN 177

12.3.5.1 Growing focus on advancements in personalized medicine to support market growth 177

TABLE 203 SPAIN: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION) 178

TABLE 204 SPAIN: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION) 178

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 205 SPAIN: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION) 178

TABLE 206 SPAIN: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION) 179

TABLE 207 SPAIN: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 179

TABLE 208 SPAIN: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION) 179

TABLE 209 SPAIN: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION) 180

12.3.6 REST OF EUROPE 180

TABLE 210 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2021-2028 (USD MILLION) 180

TABLE 211 REST OF EUROPE: CUSTOM ANTIBODY MARKET FOR ANTIBODY DEVELOPMENT, BY TYPE, 2021-2028 (USD MILLION) 181

TABLE 212 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY TYPE, 2021-2028 (USD MILLION) 181

TABLE 213 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2021-2028 (USD MILLION) 181

TABLE 214 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 182

TABLE 215 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY INDICATION, 2021-2028 (USD MILLION) 182

TABLE 216 REST OF EUROPE: CUSTOM ANTIBODY MARKET, BY END USER, 2021-2028 (USD MILLION) 182

12.3.7 EUROPE: RECESSION IMPACT 183

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Custom Antibody Market by Service (Development, Purification, Labelling), Type (Monoclonal, Recombinant), Source (Rabbit, Mice), Application (Research, Therapeutics), Indication (Oncology, Immunology), End User (Biopharma, CROs) - Global Forecast to 2028

Market Report | 2023-02-28 | 278 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scottis-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scottis-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scottis-international.com

www.scottis-international.com

Zip Code*

Country*

Date

2026-03-03

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com